Analysis of miRNA Expression in Endometrial Cancer
MIRCE
Identification of miRNAs in Endometrial Cancer as Novel Diagnostic and Prognostic Biomarkers
1 other identifier
observational
150
1 country
1
Brief Summary
The TCGA project identified four distinct prognostic groups of endometrial carcinoma (EC) based on molecular alterations: (i) the ultramutated subtype that encompasses POLE mutated (POLE) cases; (ii) the hypermutated subtype, characterized by MisMatch Repair deficiency (MMRd); (iii) the copy-number high subtype, with p53 abnormal/mutated features (p53abn); (iv) the copy-number low subtype, known as No Specific Molecular Profile (NSMP). Although the prognostic value of TCGA molecular classification, NSMP carcinomas present a wide variability in molecular alterations and biological aggressiveness. Given that the study aims to evaluate the miRNA expression profile to identify novel potential biomarkers to better stratify the EC patients, taking into account the molecular status
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2021
CompletedFirst Submitted
Initial submission to the registry
April 10, 2021
CompletedFirst Posted
Study publicly available on registry
April 15, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
September 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2022
CompletedJuly 21, 2022
July 1, 2022
1.4 years
April 10, 2021
July 19, 2022
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evaluation of miRNA expression based on the 4 molecular groups
Evaluate miRNA expression based on the 4 molecular groups recently identified
1 year
Secondary Outcomes (1)
Integration of molecular results with clinico-pathological data
1 year
Eligibility Criteria
women with endometrial cancer
You may qualify if:
- age\>18yo
- histological diagnosis of endometrial cancer
- tumor resection
- patient's informed consent
You may not qualify if:
- patients with other neoplasia within the last 5 years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
IRCCS- Azienda Ospedaliera-Universitaria di Bologna
Bologna, Bo, 40138, Italy
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Anna Myriam Perrone
IRCCS Azienda Ospedaliera-Universitaria di Bologna
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- RETROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal investigator
Study Record Dates
First Submitted
April 10, 2021
First Posted
April 15, 2021
Study Start
April 1, 2021
Primary Completion
September 1, 2022
Study Completion
December 1, 2022
Last Updated
July 21, 2022
Record last verified: 2022-07
Data Sharing
- IPD Sharing
- Will not share